Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $27.22 Consensus Price Target from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX) has earned an average rating of “Hold” from the nine analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $27.22.

PCRX has been the subject of several analyst reports. Barclays upped their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. HC Wainwright lifted their target price on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a report on Friday, February 28th. Needham & Company LLC boosted their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price target for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th.

Pacira BioSciences Stock Down 4.9 %

Shares of NASDAQ:PCRX opened at $23.10 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The stock has a market cap of $1.07 billion, a P/E ratio of -11.38 and a beta of 0.70. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $31.67. The firm has a fifty day moving average price of $24.88 and a 200 day moving average price of $20.38.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Sterling Capital Management LLC grew its stake in Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after buying an additional 1,208 shares during the period. Ancora Advisors LLC purchased a new stake in shares of Pacira BioSciences during the 4th quarter valued at about $26,000. Caitlin John LLC boosted its holdings in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after acquiring an additional 1,776 shares during the period. Nisa Investment Advisors LLC grew its position in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after acquiring an additional 2,749 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after buying an additional 513 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.